ArticleClinical oral investigations2025
The role of a local application of 10% doxycycline gel in the prevention of medication-related osteonecrosis of the jaw in rats.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanism-Oriented Biomaterial Strategies for Bone Regeneration in BRONJ: From Pathological Barriers to Evidence-Matched Repair.Biomolecules · 2026Review
- Distinct Osteogenic Profiles of Tetracyclines from Different Generations in an Ex Vivo Embryonic Chick Femur Model.International journal of molecular sciences · 2026Article
- A scientometric study on research trends and characteristics of medication-related osteonecrosis of the jaw.Journal of dental sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate doxycycline on the prevention of MRONJ. MATERIALS AND
methodsSeventy-two Wistar rats were sorted into 3 groups and subjected to tooth extractions. The first group received systemic saline solution (SAL), the second received zoledronic acid (ZA), and the third, besides the systemic ZA, the post-extraction socket received local application of doxycycline (DOXI) gel. Samples were collected and analyzed at 7, 14, and 28 postoperative days.
resultsDOXI group presented higher percentage of vital bone area as compared with ZA at 7 (p = 0.0058), 14 (p < 0.0001), and 28 days (p < 0.0001). TRAP immunolabeling was lower in ZA and DOXI at 7 and 14 days, while OCN immunolabeling was similar between the ZA and DOXI, except at 7 days. At 14 and 28 days, DOXI group presented more collagen type 3 and 1 (p < 0.0001) as compared with ZA. RUNX2, ALP, OCN, and RANKL gene expression was downregulated in ZA at 7 days. Conversely, DOXI upregulated these markers and OPG over time (p < 0.05).
conclusionDoxycycline is an effective local agent for preventing MRONJ, favoring alveolar bone healing. CLINICAL RELEVANCE: Although widely studied, MRONJ remains a significant challenge in dentistry. The search for preventive methods is important to assure safety for in patients under antiresorptive therapy that demand surgical dental treatment. Doxycycline is well-established in dentistry, and the proposal of using this medication as a gel makes it more appealing since it is applied locally and has negligible adverse effects.
Indexed as
Identifiers
40131553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.